International Stem Cell Corporation Announces Positive Results From In Vivo Animal Study of Parkinson's Disease
CARLSBAD, CA -- (Marketwire) -- 02/04/13 -- International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company") a California-based biotechnology company, today announced positive 12-week results from its pre-clinical in vivo Parkinson's disease study. The primary goal of this behavioral study was to demonstrate the therapeutic benefits of neuronal cells derived from human parthenogenetic stem cell (hpSC) line in a rat model of Parkinson's disease (PD).
Parkinson's disease is a common neurodegenerative disorder caused by a progressive degeneration of dopamine-producing neurons resulting in gradual dysfunction of the motor system and can eventually lead to death. Pharmacological treatments are useful in the relatively early stage of the disease, but the continuous use of pro-dopaminergic medication eventually becomes ineffective and can cause some of the motor symptoms to worsen.
Our proprietary technology is based on a homogeneous population of neuronal cells (NCs) derived from homozygous hpSCs through a scalable and efficient method, developed by ISCO's R&D team. These parthenogenetically-derived NCs are cryopreservable and can become neurons once they are implanted into the brain. As such, they hold significant therapeutic potential not only because they can differentiate into dopamine-producing neurons, but also because these cells deliver trophic factors that may be able to provide a level of protection to existing neurons affected by the disease.
The animal model used in this study is the 6-OHDA lesioned rat, a well-established and validated model of PD which has been used extensively in the development and testing of drugs for the treatment of PD. The pharmacological induction of rotational behavior in rats is widely used to assess the effects of lesions and potential of cell therapy to effectively replace the dopaminergic system in the rat brain and thus serves as a model of PD. The experimental rats with unilateral dopamine (6-OHDA) lesions survived the inoculation of cells into the brain and signs of improvement in rotational behavior of these animals were clearly observed. Correlational analysis of rotation intensity demonstrated a difference between the drug effects in the control group vs. experimental (transplanted) group of animals. These interim results demonstrate that a single injection of hpSC-derived neuronal cells into the striatum of rats with induced PD symptoms can lead to a significant slowdown in the progression of the disease.
Dr. Ruslan Semechkin, Vice President - head of R&D, comments: "This is a very important result for our pre-clinical Parkinson's program. The initial in vivo results are very encouraging and show the therapeutic promise of hpSC-derived neuronal cells in the treatment of individuals with Parkinson's disease. Results from this behavioral study will be presented and discussed together with the results of non-human primate study before the end of the first quarter of 2013"
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
Safe harbor statement
Statements pertaining to anticipated developments, the potential use of technologies to develop therapeutic products and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects" or "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
International Stem Cell Corporation
Dr. Simon Craw
Executive Vice President
Dr. Ruslan Semechkin
Vice President, R&D
Senior Vice President